Posted inEuronext
Lonza expands Bioconjugation facility and announces approval of third commercial ADC
BASEL, SWITZERLAND: Lonza has announced the start of expansion to its bioconjugation facility in Visp, Switzerland together with the successful commercial approval of a third antibody-drug-conjugate (ADC) produced at the…